|
1）Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015; 41: 636-48
|
|
|
|
2）Sakurai Y, Nishimura A, Kennedy G, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015; 6: e94
|
|
|
|
|
|
3）大竹一嘉，櫻井佑一，西田晴行，他．新規カリウムイオン競合型アシッドブロッカー ボノプラザンフマル酸塩(vonoprazan fumarate TAK-438)の特徴．Prog Med. 2014; 34: 2183-94
|
|
|
|
|
4）Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011; 337: 797-804
|
|
|
|
|
|
5）Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011; 81: 1145-51
|
|
|
|
|
|
6）Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluoro-phenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011; 339: 412-20
|
|
|
|
|
|
7）Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluoro-phenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012; 55: 4446-56
|
|
|
|
|
|
8）村上和成，西村 章，浅香正博．TAK-438のH. pylori一次除菌における無作為二重盲検比較試験．日本消化器病学会雑誌．2014; 111: A632
|
|
|
|
|
|
9）蘆田 潔，岩切勝彦，梅垣英次，他．TAK-438の逆流性食道炎（治療）における第3相二重盲検比較試験．日本消化器病学会雑誌．2014; 111: A853
|
|
|
|
|
|
10）梅垣英次，蘆田 潔，岩切勝彦，他．TAK-438の逆流性食道炎（維持療法）における第3相二重盲検比較試験．日本消化器病学会雑誌．2014; 111: A834
|
|
|
|
|